The findings suggest that methods developed in high-income settings to check kidney function are not accurate for many people in Africa. Researchers from the African Research on Kidney… read more.
A new algorithm developed by researchers at Columbia University can analyze thousands of variants across the genome and estimate a person’s risk of developing chronic kidney disease —… read more.
GlaxoSmithKline plc announced that the European Medicines Agency (EMA) validated the marketing authorisation application (MAA) for daprodustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the… read more.
Researchers report that patients diagnosed with type 2 diabetes in their youth are, by young adulthood, at risk of serious complications. The findings from the TODAY2 study (Treatment… read more.
The FDA has issued a complete response letter (CRL) regarding the New Drug Application (NDA) for roxadustat for the treatment of anaemia of chronic kidney disease (CKD), in… read more.
GlaxoSmithKline plc announced positive headline results from five studies of the Phase III ASCEND programme, evaluating the efficacy and safety profile of daprodustat, an investigational oral hypoxia-inducible factor… read more.
Bayer announced the FDA has approved Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death,… read more.
Advicenne announces that the Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Sibnayal (ADV 7103) in the UK, for the treatment of distal renal… read more.
Article written by Gary Finnegan. Chronic kidney disease affects approximately 700 million people worldwide with many going on to require dialysis. Now a new enzyme has been discovered… read more.
AstraZeneca’s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage… read more.
Article written by Bruce Sylvester The diabetes drug canagliflozin, which has already shown efficacy in slowing kidney disease, is also effective among patients with advanced kidney disease.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
